Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:43 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 2,101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable saline Clear all
Completed Phase 4 Interventional

Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation

NCT00974272
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Interventions
Exenatide, Normal Saline
Drug · Other
Lead sponsor
Carl T. Hayden VA Medical Center
Federal
Eligibility
35 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2009 · Synced Nov 3, 2026, 5:43 PM EST
Completed Not applicable Interventional Results available

Subcutaneous Botulinum Toxin for Cutaneous Allodynia

NCT00725322
View directory record Official record
Conditions
Pain
Interventions
Botulinum Toxin A, Placebo - Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2017 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 1Phase 2 Interventional

Efficacy of Epidural Etanercept in the Treatment of Sciatica

NCT00364572
View directory record Official record
Conditions
Sciatica
Interventions
epidural injection of etanercept, placebo (control procedure)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2009 · Synced Nov 3, 2026, 5:43 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

HPV Vaccine Reduced Dose

NCT06799494
View directory record Official record
Conditions
HPV
Interventions
Gardasil-9, Lidocaine injection, Lorazepam
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Withdrawn Phase 2Phase 3 Interventional

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

NCT04345666
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Testosterone cypionate, Placebos
Drug
Lead sponsor
Orthopedic Institute, Sioux Falls, SD
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Nov 3, 2026, 5:43 PM EST
Completed Not applicable Interventional

Local Infiltration Analgesia for Hip Arthroscopy

NCT01454518
View directory record Official record
Conditions
Pain
Interventions
Infiltration of local anesthetic, Normal Saline Injection
Procedure
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

NCT06000410
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Amniotic Suspension Allograft, Placebo
Biological · Drug
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
41
States / cities
Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 2Phase 3 Interventional Results available

Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence

NCT00758420
View directory record Official record
Conditions
Varicose Veins
Interventions
Varisolve (Polidocanol Endovenous Microfoam), Agitated Saline
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Scottsdale, Arizona • New York, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Nov 3, 2026, 5:43 PM EST
Terminated Phase 4 Interventional Results available

Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing

NCT00934661
View directory record Official record
Conditions
Hip Arthroplasty
Interventions
Extended Release Epidural Morphine (EREM), Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of BMN 111 Administered to Healthy Adult Volunteers

NCT01590446
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Normal Saline
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
22 Years to 45 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 1 Interventional

The Biomechanical Effects of Flaccid Paralysis Induced by Botulinum Toxin a After Damage Control Laparotomy

NCT01495962
View directory record Official record
Conditions
Wound; Abdomen, Abdominal Wall
Interventions
Botulinum Toxin Type A, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Rochester, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Nov 3, 2026, 5:43 PM EST
Recruiting Phase 2 Interventional

Efficacy and Safety Study of TPX-115 on Partial-thickness Rotator Cuff Tear

NCT07219654
View directory record Official record
Conditions
Partial Thickness Rotator Cuff Tears
Interventions
TPX-115, Cryopreserving hyaluronic acid medium, Saline
Biological · Other · Drug
Lead sponsor
Tego Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
La Mesa, California • Deerfield Beach, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Vaginal Injection of Platelet Rich Plasma for Sexual Function

NCT05769283
View directory record Official record
Conditions
Sexual Behavior, Sexual Activity
Interventions
Platelet Rich Plasma, Saline
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 2 Interventional Results available

Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery

NCT01444924
View directory record Official record
Conditions
Gynecologic Cancer, Post-operative Pain
Interventions
Bupivicaine, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 3 Interventional

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT06347003
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Garden Grove, California • Lake Forest, California • Montclair, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Withdrawn Phase 1 Interventional Accepts healthy volunteers

SARS Coronavirus Vaccine (SARS-CoV)

NCT00533741
View directory record Official record
Conditions
Coronavirus (SARS-CoV)
Interventions
Aluminum hydroxide, Placebo, SARS-CoV
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496
View directory record Official record
Conditions
Hypereosinophilic Syndrome
Interventions
Mepolizumab 300 mg, Placebo matching mepolizumab, Active OCS capsules (5 mg prednisolone or prednisone), Placebo matching OCS capsules
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
San Diego, California • New Haven, Connecticut • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Nov 3, 2026, 5:43 PM EST
Withdrawn Phase 2Phase 3 Interventional

Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction

NCT02803073
View directory record Official record
Conditions
Hypogonadism, Acute Myocardial Infarction: Rehabilitation Phase
Interventions
Testosterone, Normal Saline
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Nov 3, 2026, 5:43 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Marcaine Post-Operative Pain Study

NCT04494880
View directory record Official record
Conditions
Effect of Drug
Interventions
Bupivacaine Injection
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
Up to 89 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Nov 3, 2026, 5:43 PM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation

NCT03647917
View directory record Official record
Conditions
Skin Aging of Face and Hands
Interventions
Platelet Rich Plasma
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

NCT05891613
View directory record Official record
Conditions
Breast Reduction
Interventions
Bupivacaine Hydrochloride, Liposomal Bupivacaine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 5:43 PM EST
Terminated Phase 2 Interventional Results available

Use of Etanercept in the Treatment of Moderate to Severe Lichen Planus

NCT00285779
View directory record Official record
Conditions
Lichen Planus
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
12
States / cities
Stanford, California • Atlanta, Georgia • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Nov 3, 2026, 5:43 PM EST
Completed Phase 3 Interventional Results available

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

NCT02526160
View directory record Official record
Conditions
X-linked Hypophosphatemia
Interventions
burosumab, Placebo
Biological · Other
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Nov 3, 2026, 5:43 PM EST